...
首页> 外文期刊>International Journal of Molecular Sciences >Combined Elevation of microRNA-196a and microRNA-196b in Sera Predicts Unfavorable Prognosis in Patients with Osteosarcomas
【24h】

Combined Elevation of microRNA-196a and microRNA-196b in Sera Predicts Unfavorable Prognosis in Patients with Osteosarcomas

机译:血清中microRNA-196a和microRNA-196b的联合升高可预测骨肉瘤患者的不良预后

获取原文
           

摘要

AimTo investigate whether the aberrant expression of microRNA (miR)-196a and miR-196b can be used as potential prognostic markers of human osteosarcoma.MethodsQuantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis was performed to detect the expression levels of miR-196a and miR-196b in osteosarcoma tissues and patients’ sera.ResultsExpression levels of miR-196a and miR-196b in osteosarcoma tissues were both significantly higher than those in noncancerous bone tissues (both p 0.001), in line with which, the serum levels of the two miRNAs were also markedly upregulated in patients with osteosarcomas compared with healthy controls (both p 0.001). Then, the elevation of serum miR-196a and miR-196b levels both more frequently occurred in osteosarcoma patients with high tumor grade (p = 0.008 and 0.01, respectively), positive metastasis (p = 0.001 and 0.006, respectively) and recurrence (p = 0.001 and 0.006, respectively). Moreover, high serum miR-196a, high serum miR-196b and conjoined expression of miR-196a/miR-196b were all independent prognostic factors for OS (overall survival) and DFS (disease-free survival) of osteosarcoma patients.ConclusionOur present data indicate the involvement of miR-196a and miR-196b upregulation in the pathogenesis of osteosarcoma. More importantly, the altered levels of circulating miR-196a and miR-196b might have great potential to serve as novel and non-invasive prognostic factors for this malignancy.
机译:目的探讨miRNA(miR)-196a和miR-196b的异常表达是否可作为人骨肉瘤的预后指标。方法采用实时定量逆转录-聚合酶链反应(qRT-PCR)分析检测其表达。结果骨肉瘤组织和患者血清中miR-196a和miR-196b的水平。结果骨肉瘤组织中miR-196a和miR-196b的表达水平均显着高于非癌性骨组织中的表达水平(p <0.001),与与健康对照组相比,骨肉瘤患者的两种miRNA的血清水平也显着上调(均p <0.001)。然后,血清miR-196a和miR-196b的水平升高在肿瘤分级高(分别为p = 0.008和0.01),转移阳性(分别为p = 0.001和0.006)和复发(p分别为0.001和0.006)。此外,高血清miR-196a,高血清miR-196b和miR-196a / miR-196b的联合表达都是骨肉瘤患者OS(总体生存)和DFS(无疾病生存)的独立预后因素。提示miR-196a和miR-196b上调参与了骨肉瘤的发病机理。更重要的是,循环miR-​​196a和miR-196b水平的改变可能具有巨大的潜力,可以作为这种恶性肿瘤的新的非侵入性预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号